Compare · ORKA vs TRIB
ORKA vs TRIB
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Trinity Biotech plc (TRIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TRIB operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.07B, about 777.2x TRIB ($7.8M).
- Over the past year, ORKA is up 493.5% and TRIB is down 69.5% - ORKA leads by 563.1 points.
- ORKA has been more active in the news (15 items in the past 4 weeks vs 9 for TRIB).
- ORKA has more recent analyst coverage (11 ratings vs 0 for TRIB).
- Company
- Oruka Therapeutics Inc.
- Trinity Biotech plc
- Price
- -
- -
- Market cap
- $6.07B
- $7.8M
- 1M return
- -6.33%
- +3.25%
- 1Y return
- +493.54%
- -69.52%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 15
- 9
- Recent ratings
- 11
- 0
Trinity Biotech plc
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Latest ORKA
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
Latest TRIB
- SEC Form EFFECT filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
- SEC Form POS AM filed by Trinity Biotech plc
- SEC Form AW filed by Trinity Biotech plc
- Amendment: SEC Form F-1/A filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- SEC Form 6-K filed by Trinity Biotech plc
- Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SEC Form 6-K filed by Trinity Biotech plc